TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Devouassoux-Shisheboran, M. AU - Genestie, C. PY - 2015 DA - 2015// TI - Pathobiology of ovarian carcinomas JO - Chin J Cancer VL - 34 UR - https://doi.org/10.5732/cjc.014.10273 DO - 10.5732/cjc.014.10273 ID - Devouassoux-Shisheboran2015 ER - TY - JOUR PY - 2011 DA - 2011// TI - Integrated genomic analyses of ovarian carcinoma JO - Nature VL - 474 UR - https://doi.org/10.1038/nature10166 DO - 10.1038/nature10166 ID - ref3 ER - TY - JOUR AU - Roy, R. AU - Chun, J. AU - Powell, S. N. PY - 2011 DA - 2011// TI - BRCA1 and BRCA2: different roles in a common pathway of genome protection JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3181 DO - 10.1038/nrc3181 ID - Roy2011 ER - TY - STD TI - Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015;107(7). doi:10.1093/jnci/djv108 ID - ref5 ER - TY - JOUR AU - Yang, D. AU - Sun, Y. AU - Hu, L. AU - Zheng, H. AU - Ji, P. AU - Pecot, C. V. PY - 2013 DA - 2013// TI - Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer JO - Cancer Cell VL - 23 UR - https://doi.org/10.1016/j.ccr.2012.12.020 DO - 10.1016/j.ccr.2012.12.020 ID - Yang2013 ER - TY - JOUR AU - Liu, G. AU - Sun, Y. AU - Ji, P. AU - Li, X. AU - Cogdell, D. AU - Yang, D. PY - 2014 DA - 2014// TI - MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer JO - J Pathol VL - 233 UR - https://doi.org/10.1002/path.4348 DO - 10.1002/path.4348 ID - Liu2014 ER - TY - JOUR AU - Sun, Y. AU - Guo, F. AU - Bagnoli, M. AU - Xue, F. X. AU - Sun, B. C. AU - Shmulevich, I. PY - 2015 DA - 2015// TI - Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer JO - Chin J Cancer VL - 34 UR - https://doi.org/10.5732/cjc.014.10284 DO - 10.5732/cjc.014.10284 ID - Sun2015 ER - TY - JOUR AU - Baumann, P. AU - West, S. C. PY - 1998 DA - 1998// TI - Role of the human RAD51 protein in homologous recombination and double-stranded-break repair JO - Trends Biochem Sci VL - 23 UR - https://doi.org/10.1016/S0968-0004(98)01232-8 DO - 10.1016/S0968-0004(98)01232-8 ID - Baumann1998 ER - TY - JOUR AU - Quiros, S. AU - Roos, W. P. AU - Kaina, B. PY - 2011 DA - 2011// TI - Rad51 and BRCA2—new molecular targets for sensitizing glioma cells to alkylating anticancer drugs JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0027183 DO - 10.1371/journal.pone.0027183 ID - Quiros2011 ER - TY - JOUR AU - Tsai, M. S. AU - Kuo, Y. H. AU - Chiu, Y. F. AU - Su, Y. C. AU - Lin, Y. W. PY - 2010 DA - 2010// TI - Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells JO - J Pharmacol Exp Ther VL - 335 UR - https://doi.org/10.1124/jpet.110.173146 DO - 10.1124/jpet.110.173146 ID - Tsai2010 ER - TY - JOUR AU - Ito, M. AU - Yamamoto, S. AU - Nimura, K. AU - Hiraoka, K. AU - Tamai, K. AU - Kaneda, Y. PY - 2005 DA - 2005// TI - Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin JO - J Gene Med VL - 7 UR - https://doi.org/10.1002/jgm.753 DO - 10.1002/jgm.753 ID - Ito2005 ER - TY - JOUR AU - Yang, Z. AU - Waldman, A. S. AU - Wyatt, M. D. PY - 2012 DA - 2012// TI - Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics JO - Biochem Pharmacol VL - 83 UR - https://doi.org/10.1016/j.bcp.2011.12.022 DO - 10.1016/j.bcp.2011.12.022 ID - Yang2012 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. AU - Tutt, A. N. AU - Johnson, D. A. AU - Richardson, T. B. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Chen, A. PY - 2011 DA - 2011// TI - PARP inhibitors: its role in treatment of cancer JO - Chin J Cancer VL - 30 UR - https://doi.org/10.5732/cjc.011.10111 DO - 10.5732/cjc.011.10111 ID - Chen2011 ER - TY - JOUR AU - Yang, D. AU - Khan, S. AU - Sun, Y. AU - Hess, K. AU - Shmulevich, I. AU - Sood, A. K. PY - 2011 DA - 2011// TI - Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JO - JAMA VL - 306 UR - https://doi.org/10.1001/jama.2011.1456 DO - 10.1001/jama.2011.1456 ID - Yang2011 ER - TY - JOUR AU - Bolton, K. L. AU - Chenevix-Trench, G. AU - Goh, C. AU - Sadetzki, S. AU - Ramus, S. J. AU - Karlan, B. Y. PY - 2012 DA - 2012// TI - Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JO - JAMA VL - 307 UR - https://doi.org/10.1001/jama.2012.20 DO - 10.1001/jama.2012.20 ID - Bolton2012 ER - TY - JOUR AU - Liu, G. AU - Yang, D. AU - Sun, Y. AU - Shmulevich, I. AU - Xue, F. AU - Sood, A. K. PY - 2012 DA - 2012// TI - Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer JO - Pharmacogenomics VL - 13 UR - https://doi.org/10.2217/pgs.12.137 DO - 10.2217/pgs.12.137 ID - Liu2012 ER -